Predict Cancer Years Early: How Blood DNA Tests Signal Risk

DNA Methylation Patterns Reveal Early Biological Shifts Years Before Diagnosis

Routine screening tests have historically been restricted to a handful of malignancies, such as Pap smears for cervical cancer and stool tests for bowel cancer. For other conditions, early identification relies on radiological imaging to spot tumors or tissue biopsies to inspect cellular irregularities, methods that vary widely in effectiveness. Minimally invasive liquid biopsies using blood or urine offer a promising alternative by spotting cancer signatures in their earliest stages.

While liquid biopsies are typically deployed post-diagnosis to analyze existing tumor DNA or monitor recurrences, a study utilizing stored blood samples from the Ontario Health Study looked deeper into the past. Researchers examined samples from 491 participants who were cancer-free at the time of collection—some of whom later developed breast or prostate cancer, while others did not. They hunted for DNA methylation differences, which act as tiny chemical switches controlling gene activity linked to immune function, inflammation, and cell growth.

Blood Cancers Tracked Across a Decade Reveal Genetic Quietness and Progression

Complementing these findings regarding solid tumors, research published in the journal Cancer Discovery by the American Association for Cancer Research tracked 30 people with myeloproliferative neoplasms (MPNs), a group of blood cancers where bone marrow overproduces blood cells. Researchers at the Wellcome Trust Sanger Institute in the U.K. monitored patient blood and bone marrow, discovering that individuals whose disease stayed stable often maintained a genetically “quiet” profile without cancer-related genetic changes.

Conversely, patients whose condition deteriorated showed DNA changes years ahead of routine blood work spotting the shift. As new groups of abnormal cells emerged and grew, the underlying trajectory became visible in the genetic data. Nine participants ultimately developed acute myeloid leukemia (AML), though their pathways varied. Some accumulated harmful mutations gradually, while others saw leukemia stem from a separate group of abnormal blood cells. Similar variations appeared in patients who developed myelofibrosis.

Medication Impacts and Clinical Implications for Precision Medicine

The study also identified treatment-related genetic changes. Hydroxyurea, a standard medication used to manage blood counts in MPN patients, leaves a recognizable pattern of minor DNA alterations in blood cells, though researchers found no evidence that the drug causes leukemia. A similar pattern was linked to azacitidine, a drug utilized for certain blood cancers. Strikingly, three individuals who received a diagnosis of “triple-negative” essential thrombocythemia—frequently categorized as a blood malignancy—displayed zero genetic indicators of cancer within their samples, suggesting that certain people assigned this condition might not actually have a malignant illness and could potentially forego extended cancer therapies.

Though the study was limited by its small sample size and demonstrated associations rather than direct cause and effect, the implications for future care are substantial. Orlando Health oncologist Abhishek Chilkulwar, who stayed completely independent of the investigation, pointed out that the majority of individuals diagnosed with MPNs are able to manage the condition for decades. Chilkulwar characterized the discoveries as a striking demonstration indicating that genetic shifts can foretell specific malignancies a decade prior to formal detection, and that their subsequent trajectory may already be ‘written’ in a patient’s cells long before doctors can see any outward sign.

This research shows that these blood cancers may reveal their future course in a person’s DNA long before any symptoms appear, a genuinely exciting scientific insight, and a step toward precision medicine in blood cancer care, Chilkulwar stated. He added that the work represents an early example of precision medicine for blood cancer prevention:

More broadly, it’s an early example of what could become precision medicine for blood cancer prevention, using a patient’s own genetic data to predict risk years in advance, then someday intervening before disease progression rather than only treating it after the fact. That’s the direction this kind of research is pointing, even though the tools to act on it aren’t fully built yet.

Ultimately, the results suggest that periodically retesting a patient’s DNA over time could give doctors a heads-up that someone’s disease is heading in a dangerous direction, well before it shows up in routine blood work, according to Chilkulwar.